Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
UCB S.A. - Pharma Sector
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01883011CT.gov A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Middle Cerebral Artery Infarction
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Piracetam (this asset) | UCB S.A. - Pharma Sector | Approved | CCC · 48 |
| Alteplase | SOS Attaque Cérébrale | P4 | BB |
| Recombinant Human Erythropoietin Alfa | Max-Planck-Institute of Experimental Medicine | P2/3 | B |
| Physiologic Sodium Chloride Solution | Max-Planck-Institute of Experimental Medicine | P2/3 | B |
| Allogeneic-Unrelated Placenta-Derived Stromal Cells, Expanded Ex Vivo | Celularity Incorporated | P2 | CCC |
| Auto-Cd34+ Cells | Imperial College London | P1/2 | CCC |
| Autologous Bone Marrow Mononuclear Cell Intra-Arterial | Post Graduate Institute of Medical Education and Research, Chandigarh | P1 | CC |
| Teonanacatl | Johns Hopkins University | P1 | CC |
| Perampanel | National Cheng Kung University | N/A | D |
+2 more in the Middle Cerebral Artery Infarction cohort
Other indications for Piracetam
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Dementia | — | P3 | CC · 45 |
| Physiological Malfunction Arising From Mental Factor | — | P3 | CC · 45 |
| Anxiety Disorder | — | P3 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- AlteplaseSOS Attaque CérébraleBB
- Recombinant Human Erythropoietin AlfaMax-Planck-Institute of Experimental MedicineB
- Physiologic Sodium Chloride SolutionMax-Planck-Institute of Experimental MedicineB
- Allogeneic-Unrelated Placenta-Derived Stromal Cells, Expanded Ex VivoCelularity IncorporatedCCC
- Auto-Cd34+ CellsImperial College LondonCCC
Citation
Floatz Terminal. Piracetam in Middle Cerebral Artery Infarction. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/piracetam-middle-cerebral-artery-infarction
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →